Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司对外提供财务资助管理办法
Governance Information Classification · 95% confidence The document is titled '对外提供财务资助管理办法' which translates to 'Measures for the Management of External Financial Assistance' and is a detailed internal policy document of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines rules, approval procedures, responsibilities, and disclosure requirements related to the company's provision of financial assistance to external parties. The document is regulatory and governance-related in nature, focusing on internal control and compliance with securities laws and stock exchange rules. It does not contain financial statements, earnings data, audit opinions, or shareholder meeting materials. It is not an announcement or a report of financial results or voting outcomes. It is a governance or compliance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3896 characters, which is substantive and not a brief announcement or certification, supporting this classification.
2025-08-25 Chinese
北京双鹭药业股份有限公司独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议工作制度' which translates to 'Independent Directors Special Meeting Work System'. It outlines the rules, responsibilities, procedures, and governance related to the independent directors' meetings within the company. It references relevant laws and regulations, the company's articles of association, and details the governance structure and meeting protocols for independent directors. There is no financial data, earnings information, or report publication announcement. The content is focused on governance practices and internal rules regarding board structure and independent directors' roles. Therefore, the document fits best under Governance Information (CGR). The document length is 2595 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2025-08-25 Chinese
北京双鹭药业股份有限公司独立董事工作制度
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the governance structure, qualifications, duties, and protections of independent directors at Beijing Shuanglu Pharmaceutical Co., Ltd. It references relevant laws, regulations, and governance practices but does not contain financial statements, audit results, or financial performance data. It is a governance-related document outlining internal rules and board structure. The document length is 9200 characters, indicating a full policy document rather than a brief announcement. Therefore, it fits best under Governance Information (CGR).
2025-08-25 Chinese
北京双鹭药业股份有限公司董事会秘书工作制度
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It details the roles, responsibilities, qualifications, appointment, and legal liabilities of the board secretary at Beijing SL Pharmaceutical Co., Ltd. It references relevant laws and regulations, company bylaws, and stock exchange rules. The content is a governance-related internal policy document rather than a financial report, earnings release, or announcement. It does not contain financial data, audit information, or shareholder voting results. It is not a report publication announcement or a regulatory filing in the usual sense but a governance practice document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is under 5,000 characters, but it is a full policy document, not a brief announcement, so RPA is not suitable.
2025-08-25 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 85% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It contains financial figures and accounting details specific to the half-year period, indicating substantive financial data. The document length is 1759 characters, which is relatively short but contains actual financial data rather than just an announcement or certification. The content aligns with a half-year or interim financial report rather than a full annual report or a simple announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 半年度财务报告" which translates to "Beijing SL Pharmaceutical Co., Ltd. Half-Year Financial Report." It covers the period from January 1, 2025, to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed consolidated and parent company financial statements such as balance sheets, income statements, cash flow statements, and changes in shareholders' equity, along with notes to the financial statements. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis rather than just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.